Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity.

Palazzolo I, Burnett BG, Young JE, Brenne PL, La Spada AR, Fischbeck KH, Howell BW, Pennuto M.

Hum Mol Genet. 2007 Jul 1;16(13):1593-603. Epub 2007 Apr 30.

2.

Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA).

Katsuno M, Tanaka F, Adachi H, Banno H, Suzuki K, Watanabe H, Sobue G.

Prog Neurobiol. 2012 Dec;99(3):246-56. doi: 10.1016/j.pneurobio.2012.05.007. Epub 2012 May 15. Review.

PMID:
22609045
3.

Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives.

Katsuno M, Adachi H, Tanaka F, Sobue G.

J Mol Med (Berl). 2004 May;82(5):298-307. Epub 2004 Feb 27. Review.

PMID:
15133611
4.
5.

Neuropathology and therapeutic intervention in spinal and bulbar muscular atrophy.

Banno H, Katsuno M, Suzuki K, Tanaka F, Sobue G.

Int J Mol Sci. 2009 Mar;10(3):1000-12. Epub 2009 Mar 10. Review.

6.

[Molecular-targeted therapy for spinal and bulbar muscular atrophy (SBMA)].

Sobue G.

Rinsho Shinkeigaku. 2010 Nov;50(11):839-41. Review. Japanese.

PMID:
21921465
7.

Molecular pathogenesis of spinal and bulbar muscular atrophy.

Merry DE.

Brain Res Bull. 2001 Oct-Nov 1;56(3-4):203-7. Review.

PMID:
11719251
8.

Transgenic mouse models of spinal and bulbar muscular atrophy (SBMA).

Katsuno M, Adachi H, Inukai A, Sobue G.

Cytogenet Genome Res. 2003;100(1-4):243-51. Review.

PMID:
14526186
9.

Current status of treatment of spinal and bulbar muscular atrophy.

Tanaka F, Katsuno M, Banno H, Suzuki K, Adachi H, Sobue G.

Neural Plast. 2012;2012:369284. doi: 10.1155/2012/369284. Epub 2012 Jun 7. Review.

10.

[Molecular-targeted therapies for spinal and bulbar muscular atrophy].

Katsuno M, Banno H, Suzuki K, Adachi H, Tanaka F, Sobue G.

Rinsho Shinkeigaku. 2009 Nov;49(11):917-20. Review. Japanese.

PMID:
20030248
11.

[Molecular pathogenesis of motor neuron diseases].

Sobue G.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2001 Feb;21(1):21-25. Review. Japanese.

PMID:
11400322
12.
13.

Trinucleotide repeat disease. The androgen receptor in spinal and bulbar muscular atrophy.

Walcott JL, Merry DE.

Vitam Horm. 2002;65:127-47. Review.

PMID:
12481545
14.

Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer.

Wang Y, Kreisberg JI, Ghosh PM.

Curr Cancer Drug Targets. 2007 Sep;7(6):591-604. Review.

PMID:
17896924
15.

Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy.

Adachi H, Waza M, Katsuno M, Tanaka F, Doyu M, Sobue G.

Neuropathol Appl Neurobiol. 2007 Apr;33(2):135-51. Review.

PMID:
17359355
16.

[Development of therapeutics for spinal and bulbar muscular atrophy (SBMA)].

Sobue G.

Rinsho Shinkeigaku. 2003 Nov;43(11):909-11. Review. Japanese.

PMID:
15152501
17.

Polyglutamine androgen receptor-mediated neuromuscular disease.

Giorgetti E, Lieberman AP.

Cell Mol Life Sci. 2016 May 17. [Epub ahead of print] Review.

PMID:
27188284
18.

Serine phosphorylation and arginine methylation at the crossroads to neurodegeneration.

Basso M, Pennuto M.

Exp Neurol. 2015 Sep;271:77-83. doi: 10.1016/j.expneurol.2015.05.003. Epub 2015 May 12. Review.

PMID:
25979114
Items per page

Supplemental Content

Write to the Help Desk